Flag of the European Union EU Clinical Trials Register Help

Clinical trials for ������������������������ .s

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43691   clinical trials with a EudraCT protocol, of which   7246   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    37,517 result(s) found for: ������������������������ .s. Displaying page 1 of 1,876.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2006-001343-55 Sponsor Protocol Number: A6061030 Start Date*: 2006-08-02
    Sponsor Name:Pfizer, S.A.
    Full Title: A PHASE 2B LONG-TERM, RANDOMIZED, OPEN-LABEL, SAFETY AND TOLERABILITY TRIAL COMPARING [S,S]-REBOXETINE (PNU-165442G) WITH ROUTINE CARE IN PATIENTS WITH POSTHERPETIC NEURALGIA (PHN).
    Medical condition: Postherpetic neuralgia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10029223 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) SE (Prematurely Ended) GB (Completed) LT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-005555-17 Sponsor Protocol Number: A6061021 Start Date*: 2006-09-04
    Sponsor Name:Pfizer AB
    Full Title: [S,S]-REBOXETINE ADD-ON TRIAL: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER TRIAL OF [S,S]-REBOXETINE IN PATIENTS WITH POSTHERPETIC NEURALGIA (PHN) CONCOMITANTLY TREATED WITH PREGAB...
    Medical condition: Postherpetic Neuralgia`
    Disease: Version SOC Term Classification Code Term Level
    8.1 10029223 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DE (Prematurely Ended) GB (Completed) ES (Completed) NL (Completed) CZ (Completed) IT (Prematurely Ended) AT (Prematurely Ended) LV (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-001307-11 Sponsor Protocol Number: A6061031 Start Date*: 2006-10-02
    Sponsor Name:Pfizer Ltd
    Full Title: A PHASE 2B LONG-TERM, RANDOMIZED, OPEN-LABEL, SAFETY AND TOLERABILITY TRIAL COMPARING [S,S]-REBOXETINE (PNU-165442G) WITH ROUTINE CARE IN PATIENTS WITH CHRONIC PAINFUL DIABETIC PERIPHERAL NEUROPATH...
    Medical condition: Diabetic Peripheral Neuropathy
    Disease: Version SOC Term Classification Code Term Level
    8.1 10012683 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) EE (Prematurely Ended) FI (Prematurely Ended) DE (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-004979-37 Sponsor Protocol Number: 06-004 Start Date*: 2006-10-27
    Sponsor Name:MediQuest Therapeutics, Inc.
    Full Title: Phase III “In-Life” Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, and Matching Placebo Gel in the Treatment and Prevention of Raynaud’s Phenomenon
    Medical condition: Moderate to severe primary Raynaud’s, OR patients with Raynaud’s phenomenon secondary to autoimmune diseases, such as scleroderma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-005216-27 Sponsor Protocol Number: 78993095 Start Date*: 2007-03-26
    Sponsor Name:HUS, Hospital for Children and Adolescents
    Full Title: Selkäytimeen annettu entsyymikorvaus mukopolysakkaridoosi I:n selkäytimen puristuman hoidossa. Kansainvälinen monikeskustutkimus. A study of intrathecal enzyme replacement therapy for spinal cord c...
    Medical condition: Mucopolysaccharidosis I H/S, lysosomal storage disease with clinical manifestations such as progressive joint stiffness, growth retardation, corneal clouding, hepatosplenomegaly, cardiac and respir...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10056887 Mucopolysaccharidosis IH/S LLT
    Population Age: Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023662-47 Sponsor Protocol Number: Rifa-2 Start Date*: 2010-12-13
    Sponsor Name:Oulu University Hospital, Department of Internal Medicine
    Full Title: PXR-aktivaation vaikutukset sokeri-, kolesteroli- ja hormonitasapainoon
    Medical condition: Terveitä vapaaehtoisia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2006-000767-28 Sponsor Protocol Number: 20061 Start Date*: 2006-09-29
    Sponsor Name:Vienna Medical University
    Full Title: Standardisierte Verlaufsbeobachtung von Patienten mit intrathekalem S(+)-Ketamin
    Medical condition: Intrathecal S(+)-ketamine is a potent option in the treatment of chronic severe neuropathic pain in cancer patients refractory to conventional therapeutic strategies (Benrath et al. 2005). However,...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-004733-41 Sponsor Protocol Number: A6061037 Start Date*: 2008-03-14
    Sponsor Name:Pfizer Ltd
    Full Title: A RANDOMIZED, DOUBLE-BLIND PLACEBO CONTROLLED TRIAL OF [S,S]-REBOXETINE IN PATIENTS WITH CHRONIC PAINFUL DIABETIC PERIPHERAL NEUROPATHY
    Medical condition: CHRONIC PAINFUL DIABETIC PERIPHERAL NEUROPATHY
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012683 Diabetic peripheral neuropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) FI (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-000474-42 Sponsor Protocol Number: CL2-90652-002 Start Date*: 2006-12-06
    Sponsor Name:INSTITUT DE RECHERCHES INTERNATIONALES SERVIER
    Full Title: Safety and effects on blood pressure of a daily dose of 0.025 to 0.135 milligram per kilogram of S 90652, a paediatric formulation of perindopril, in hypertensive children having received S 90652 -...
    Medical condition: Arterial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.1 10047065 - Vascular disorders 10015488 Essential hypertension PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-002979-40 Sponsor Protocol Number: 2006.05 Start Date*: 2006-08-07
    Sponsor Name:LUMC
    Full Title: Pharmacokinetic-pharmacodynamic modeling of S(+)-ketamine in healthy volunteers
    Medical condition: Healthy volunteers
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004568-37 Sponsor Protocol Number: INV543 Start Date*: 2018-11-30
    Sponsor Name:Nova Laboratories Limited
    Full Title: A prospective open label, pharmacokinetic study of an oral hydroxyurea solution in children with sickle cell anemia
    Medical condition: Sickle Cell Anaemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10040641 Sickle cell anaemia PT
    20.0 10010331 - Congenital, familial and genetic disorders 10040641 Sickle cell anaemia PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2020-004225-22 Sponsor Protocol Number: CSEG101A2401B Start Date*: 2021-05-03
    Sponsor Name:Novartis Pharma AG
    Full Title: An Open-label, Multi-center, Phase IV, Rollover Study for Patients with Sickle Cell Disease who have Completed a Prior Novartis-Sponsored Crizanlizumab Study
    Medical condition: Sickle Cell Disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    20.1 10010331 - Congenital, familial and genetic disorders 10002077 Anaemia sickle cell LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing) DE (Ongoing) ES (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-003601-66 Sponsor Protocol Number: CSEG101ANL01T Start Date*: 2021-07-14
    Sponsor Name:Amsterdam UMC - AMC
    Full Title: The Effect of Crizanlizumab on Cerebral Perfusion and Oxygenation in Sickle Cell Patients
    Medical condition: Sickle Cell Disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-001351-13 Sponsor Protocol Number: APHP201133 Start Date*: 2021-11-26
    Sponsor Name:Assistance Publique des Hôpitaux de Paris(AP-HP)
    Full Title: Interest of famotidine in reducing endothelial expression of P-selectin in children with sickle cell disease: pilot study, single-center, prospective, non-comparative
    Medical condition: major sickle cell syndrome
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-005889-40 Sponsor Protocol Number: ABR-15108 Start Date*: 2007-08-14
    Sponsor Name:Academic Medical Centre
    Full Title: N-Acetylcysteine for Treatment of Sickle Cell Disease
    Medical condition: Patients homozygous for sickle cell disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10040644 Sickle cell disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-004018-15 Sponsor Protocol Number: V710-003 Start Date*: 2008-01-17
    Sponsor Name:Merck Sharp & Dohme (Sweden) AB
    Full Title: A Randomized, Multicenter, Double-Blind, Group-Sequential Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Single Dose of Merck 0657nI Staphylococcus aureus Vaccine (V710) in Adult P...
    Medical condition: Staphylococcus aureus bacteremia Staphylococcus aureus mediastinitis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10058887 Staphylococcus aureus bacteremia LLT
    14.0 10021881 - Infections and infestations 10066413 Staphylococcus aureus mediastinitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DE (Prematurely Ended) BE (Completed) ES (Prematurely Ended) FI (Prematurely Ended) GB (Prematurely Ended) IT (Prematurely Ended) AT (Completed) FR (Prematurely Ended) IE (Prematurely Ended) DK (Prematurely Ended) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-004848-29 Sponsor Protocol Number: NN6535-4730 Start Date*: 2021-04-29
    Sponsor Name:Novo Nordisk A/S
    Full Title: A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer´s disease (EVOKE)
    Medical condition: Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing) CZ (Ongoing) DE (Ongoing) FI (Ongoing) IE (Ongoing) SK (Ongoing) NL (Ongoing) AT (Ongoing) BE (Ongoing) SI (Ongoing) DK (Ongoing) GR (Ongoing) PL (Ongoing) NO (Ongoing) PT (Ongoing) BG (Ongoing) IT (Ongoing) FR (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-002119-81 Sponsor Protocol Number: MEC-2018-091 Start Date*: 2018-09-05
    Sponsor Name:Erasmus MC
    Full Title: Carriage of S. aureus and interaction with the nasal microbiome
    Medical condition: S. aureus carriage
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2004-002802-31 Sponsor Protocol Number: PENT-IBD-CH CZ Start Date*: 2005-01-25
    Sponsor Name:Ferring-Leciva, a.s.
    Full Title: Multicentre, Controlled, Randomised, Open, Cross-over Study Comparing the Acceptability of Pentasa® Sachets versus Pentasa® tbl. 500mg in Children with Crohn´s Disease
    Medical condition: children patients with the Crohn s disease in any stage (where mesalazine treatment is appropriate)
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2009-017091-25 Sponsor Protocol Number: P081110 Start Date*: 2010-07-09
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Quantification de la régression de l'albuminurie et de l'atteinte endothéliale dans une population de patients drépanocytaires homozygotes hyperfiltrants traités par inhibiteurs du système rénine-...
    Medical condition: Drépanocytose homozygote présentant une microalbuminurie associée à une hyperfiltration glomérulaire
    Disease: Version SOC Term Classification Code Term Level
    8.1 10040644 drépanocytose PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2023 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA